[Perioperative chemotherapy of squamous cell cancer of the esophagus].
In the majority of patients with esophageal cancer local tumor infiltration and/or distant metastases are responsible for the poor prognosis. Therefore to improve life expectancy additional modalities--chemotherapy alone or in combination with simultaneous radiation--have been introduced perioperatively. In spite of a possible increase of resectability convincing data are lacking which could argue for an uncontrolled introduction of the neoadjuvant approach outside investigational studies in early tumor stages (T1, T2).
Fink
U
U
Chirurgische Klinik und Poliklinik, TUM Klinikum rechts der Isar, München.
Pfeiffer
G
G
Gossmann
A
A
Preusser
P
P
Wilke
H J
HJ
Siewert
J R
JR
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D006801:Humans; D009367:Neoplasm Staging; D015996:Survival Rate